• In recent months, Cardinal Health has entered the second half of 2026 with momentum in specialty pharmaceuticals, supported by demand for oncology therapies, GLP-1 products, branded medicines, and chronic-care acquisitions such as Advanced Diabetes Supply.
• This push into higher-growth, higher-margin areas is reshaping Cardinal Health’s business mix, widening its exposure to specialty drug distribution and chronic care services.
• We’ll now examine how accelerating specialty pharmaceutical demand may influence Cardinal Health’s existing investment narrative and forward-looking risk–reward balance.

Invest in the nuclear renaissance through our list of 90 elite nuclear energy infrastructure plays powering the global AI revolution.

Cardinal Health Investment Narrative Recap

To own Cardinal Health today, you need to believe its pivot toward specialty pharmaceuticals and chronic care can offset thin distribution margins and justify a premium share price. The latest news around oncology, GLP-1 and branded drug demand reinforces the near term earnings catalyst, while the biggest risk remains pressure on margins from regulation, drug pricing and potential contract losses. Overall, the impact of this news on that risk profile is incremental rather than transformative.

One recent announcement that stands out alongside this specialty momentum is Cardinal Health’s continued share repurchase activity, with US$1,733.96 million spent under its 2023 buyback to date. For investors watching how the company balances growth investments in specialty and chronic care against returns of capital, this combination of expansion and buybacks is an important part of the near term story.

Yet even as specialty growth builds, investors should be aware that concentrated customer relationships and contract expirations...

Cardinal Health's narrative projects $314.4 billion revenue and $2.3 billion earnings by 2029. This requires 7.8% yearly revenue growth and about a $0.7 billion earnings increase from $1.6 billion today.

Uncover how Cardinal Health's forecasts yield a $245.27 fair value, a 9% upside to its current price.

Exploring Other Perspectives

Four members of the Simply Wall St Community place Cardinal Health’s fair value between US$190 and about US$493 per share, underscoring how far apart individual views can be. Against that backdrop, the recent specialty pharmaceutical momentum and higher margin focus are key factors many will weigh when thinking about the company’s ability to defend earnings if regulation or pricing pressure intensifies.

Explore 4 other fair value estimates on Cardinal Health - why the stock might be worth 16% less than the current price!

Reach Your Own Conclusion

Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

• A great starting point for your Cardinal Health research is our analysis highlighting 2 key rewards and 2 important warning signs that could impact your investment decision.
• Our free Cardinal Health research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Cardinal Health's overall financial health at a glance.

Contemplating Other Strategies?

Our daily scans reveal stocks with breakout potential. Don't miss this chance:

• Find 45 companies with promising cash flow potential yet trading below their fair value.
• AI is about to change healthcare. These 40 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.
• The future of work is here. Discover the 33 top robotics and automation stocks leading the charge in AI-driven automation and industrial transformation.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.